148 related articles for article (PubMed ID: 26552493)
1. Infusing IVIG through Community Care Access Services in Patients with CIDP.
Katzberg HD; Rasutis V; Bril V
Can J Neurol Sci; 2016 Mar; 43(2):326-8. PubMed ID: 26552493
[No Abstract] [Full Text] [Related]
2. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
[TBL] [Abstract][Full Text] [Related]
3. Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.
Mielke O; Bril V; Cornblath DR; Lawo JP; van Geloven N; Hartung HP; Lewis RA; Merkies ISJ; Sobue G; Durn B; Shebl A; van Schaik IN;
J Peripher Nerv Syst; 2019 Mar; 24(1):72-79. PubMed ID: 30672067
[TBL] [Abstract][Full Text] [Related]
4. Variability in intravenous immunoglobulin G regimens for autoimmune neuromuscular disorders.
Broyles R; Rodden L; Riley P; Berger M
Postgrad Med; 2013 Mar; 125(2):65-72. PubMed ID: 23816772
[TBL] [Abstract][Full Text] [Related]
5. Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; Fokkink WR; Brusse E; Vrancken AFJE; Eftimov F; Notermans NC; van der Kooi AJ; Merkies ISJ; Jacobs BC; van Doorn PA
J Peripher Nerv Syst; 2017 Dec; 22(4):425-432. PubMed ID: 29092099
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
Rajabally YA; Afzal S
J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
[TBL] [Abstract][Full Text] [Related]
7. Acute motor response following a single IVIG treatment course in chronic inflammatory demyelinating polyneuropathy.
Harbo T; Andersen H; Jakobsen J
Muscle Nerve; 2009 Apr; 39(4):439-47. PubMed ID: 19229876
[TBL] [Abstract][Full Text] [Related]
8. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
Hughes RA
Expert Rev Neurother; 2009 Jun; 9(6):789-95. PubMed ID: 19496683
[TBL] [Abstract][Full Text] [Related]
9. Octagam
Wietek S
Neurodegener Dis Manag; 2018 Aug; 8(4):227-231. PubMed ID: 29517417
[TBL] [Abstract][Full Text] [Related]
10. The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin.
Cocito D; Serra G; Falcone Y; Paolasso I
J Peripher Nerv Syst; 2011 Jun; 16(2):150-2. PubMed ID: 21692916
[No Abstract] [Full Text] [Related]
11. Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
Merkies ISJ; van Schaik IN; Léger JM; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Durn BL; Cornblath DR; De Bleecker JL; Sommer C; Robberecht W; Saarela M; Kamienowski J; Stelmasiak Z; Tackenberg B; Mielke O;
J Peripher Nerv Syst; 2019 Mar; 24(1):48-55. PubMed ID: 30672091
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of chronic inflammatory polyradiculoneuropathy].
Nicolas G
Rev Med Interne; 2008 Jun; 29 Spec No 2():1-8. PubMed ID: 18927988
[TBL] [Abstract][Full Text] [Related]
13. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
Gorson KC; Natarajan N; Ropper AH; Weinstein R
Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
[TBL] [Abstract][Full Text] [Related]
14. Motor unit number index (MUNIX) in chronic inflammatory demyelinating polyneuropathy: A potential role in monitoring response to intravenous immunoglobulins.
Lawley A; Seri S; Rajabally YA
Clin Neurophysiol; 2019 Oct; 130(10):1743-1749. PubMed ID: 31400577
[TBL] [Abstract][Full Text] [Related]
15. Optimization of intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy evaluated by grip strength measurement.
Kokubun N; Sada T; Yuki N; Okabe M; Hirata K
Eur Neurol; 2013; 70(1-2):65-9. PubMed ID: 23796651
[TBL] [Abstract][Full Text] [Related]
16. Modulatory effects on axonal function after intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy.
Lin CS; Krishnan AV; Park SB; Kiernan MC
Arch Neurol; 2011 Jul; 68(7):862-9. PubMed ID: 21747028
[TBL] [Abstract][Full Text] [Related]
17. Chronic Inflammatory Demyelinating Polyneuropathy: Time to Maximal Recovery in Patients Receiving Intravenous Immunoglobulin Therapy.
Opala AR; Kennedy K; Baker SK
Can J Neurol Sci; 2020 Jul; 47(4):531-537. PubMed ID: 32279669
[TBL] [Abstract][Full Text] [Related]
18. Investigations and treatment of chronic inflammatory demyelinating polyradiculoneuropathy and other inflammatory demyelinating polyneuropathies.
Tracy JA; Dyck PJ
Curr Opin Neurol; 2010 Jun; 23(3):242-8. PubMed ID: 20389243
[TBL] [Abstract][Full Text] [Related]
19. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP.
Nobile-Orazio E; Cocito D; Jann S; Uncini A; Messina P; Antonini G; Fazio R; Gallia F; Schenone A; Francia A; Pareyson D; Santoro L; Tamburin S; Cavaletti G; Giannini F; Sabatelli M; Beghi E;
J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):729-34. PubMed ID: 25246645
[TBL] [Abstract][Full Text] [Related]
20. Severe Chronic Inflammatory Demyelinating Polyneuropathy Ameliorated following High-dose (3 g/kg) Intravenous Immunoglobulin Therapy.
Seino Y; Nakamura T; Hirohata M; Kawarabayashi T; Okushima T; Shoji M
Intern Med; 2019 Mar; 58(6):855-859. PubMed ID: 30449785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
